PARVB Antibody

What is PARVB and why is it important in research?

PARVB (parvin, beta) is an actin-binding protein with functionality in extracellular matrix binding. It plays crucial roles in cell adhesion and migration processes. Recent studies have identified PARVB as a potential biomarker for various cancers, particularly malignant melanoma. Research indicates that PARVB is overexpressed in malignant melanoma and predicts poor prognosis of patients, making it an important target for cancer research . The protein has a calculated molecular weight of 42 kDa, though it is often observed at both 42 kDa and 45 kDa in Western blots . Understanding PARVB's functions provides insights into cellular adhesion mechanisms and potential therapeutic targets for cancer treatment.

What applications are PARVB antibodies suitable for?

PARVB antibodies can be used in multiple experimental applications:

These antibodies have been validated in published research for knockdown/knockout (KD/KO) studies, Western blot, and immunofluorescence applications . While these are standard applications, it's important to optimize the concentration for each specific experimental system to achieve optimal results, as sensitivity may vary depending on the particular sample type and experimental conditions.

How do I select the appropriate PARVB antibody for my research?

Selection of the appropriate PARVB antibody depends on several factors:

• Species reactivity: Determine if the antibody cross-reacts with your model organism. For example, some PARVB antibodies show reactivity with human, mouse, and rat samples .

• Application compatibility: Ensure the antibody is validated for your intended application (WB, IHC, IF, etc.).

• Antibody format: Consider whether you need a conjugated antibody (like Janelia Fluor® 549) for direct visualization or an unconjugated antibody for flexibility in secondary detection .

• Clonality: Polyclonal antibodies offer higher sensitivity by recognizing multiple epitopes, while monoclonal antibodies provide higher specificity and batch consistency.

• Host species: Consider potential cross-reactivity issues, especially when working with mouse samples and mouse-derived antibodies, which may require Mouse-On-Mouse blocking reagents to reduce background signal .

• Validation data: Review performance in published literature and manufacturer validation data to ensure reliability in your specific experimental context.

What are the optimal conditions for using PARVB antibodies in immunohistochemistry?

For optimal immunohistochemistry (IHC) results with PARVB antibodies:

• Antigen retrieval: Use TE buffer at pH 9.0 for optimal antigen retrieval, though citrate buffer at pH 6.0 can serve as an alternative .

• Antibody dilution: Begin with a dilution range of 1:50-1:500 and optimize based on your specific tissue type and fixation method .

• Staining evaluation: Consider using a scoring system similar to that described in research literature, where staining intensity is scored as: 0 (negative), 1 (weakly positive), 2 (moderately positive), and 3 (strongly positive). The percentage of positivity can be scored as: 0 (<5%), 1 (5-25%), 2 (>25-50%), 3 (>50-75%), and 4 (>75%). The final score can be calculated by multiplying these values and interpreted as low (≤4), high (4-8), or very high (≥9) expression .

• Controls: Include appropriate positive controls (such as human stomach tissue) and negative controls (omitting primary antibody) to validate staining specificity .

• Background reduction: When using mouse-derived antibodies on mouse tissues, employ Mouse-On-Mouse blocking reagents to reduce nonspecific background staining .

The evaluation should ideally involve multiple independent observers who are blind to specimen details to ensure unbiased assessment of staining patterns.

How should I optimize Western blot protocols for PARVB detection?

For optimal Western blot detection of PARVB:

• Sample preparation: Use appropriate lysis buffers that preserve protein integrity. PARVB is primarily detected in cellular fractions from tissues like heart and spleen or cell lines like HeLa .

• Protein loading: Load 20-30 μg of total protein per lane for cellular samples.

• Antibody dilution: Start with a 1:5000 dilution for the primary antibody, but be prepared to optimize in a range from 1:5000 to 1:50000 depending on your specific experimental system and antibody batch .

• Expected bands: Look for bands at both 42 kDa (calculated molecular weight) and 45 kDa (observed in some samples) .

• Incubation conditions: For primary antibody, incubate overnight at 4°C; for secondary antibody, incubate for 1-2 hours at room temperature.

• Controls: Include positive controls such as HeLa cell lysate, and consider knockdown/knockout samples as negative controls when available, given that PARVB antibodies have been validated in such systems .

• Optimization: If signal is weak, consider increasing antibody concentration or extending incubation time; if background is high, increase blocking time or washing steps.

What considerations are important when using PARVB antibodies for immunofluorescence studies?

Key considerations for immunofluorescence with PARVB antibodies include:

• Fixation method: Optimize between paraformaldehyde (4%, 10-15 minutes) for structural preservation or methanol (-20°C, 10 minutes) for better epitope accessibility.

• Antibody dilution: Start with a dilution range of 1:200-1:800 for primary antibody and optimize based on signal-to-noise ratio .

• Permeabilization: Use 0.1-0.3% Triton X-100 for adequate penetration of antibodies into fixed cells.

• Blocking: Implement thorough blocking (typically 5-10% normal serum from the species of the secondary antibody) to minimize nonspecific binding.

• Detection system: When using directly conjugated antibodies like PARVB Antibody with Janelia Fluor® 549, adjust exposure settings to accommodate the specific fluorophore properties .

• Controls: Include appropriate controls to verify staining specificity, particularly important for co-localization studies with other cellular components.

• Species considerations: When using mouse-derived antibodies on mouse samples, use specific blocking reagents to reduce background. As noted in the product literature: "Mouse-On-Mouse blocking reagent may be needed for IHC and ICC experiments to reduce high background signal" .

How does PARVB expression vary across different tissues and cell types?

PARVB expression patterns show notable tissue and cell-type specificity:

• Normal tissues: PARVB is expressed in multiple tissues, with validated detection in human stomach tissue, mouse spleen tissue, mouse heart tissue, and rat heart tissue . This suggests importance in both epithelial and muscle tissues.

• Cell lines: Reliable detection has been demonstrated in HeLa cells, indicating expression in epithelial-derived cancer cell lines .

• Cancer tissues: Research indicates PARVB is overexpressed in malignant melanoma compared to normal tissues. Pan-cancer analysis has shown aberrant expression across various tumor types .

• Immune correlation: Higher PARVB expression levels have been inversely correlated with immune cell infiltration in melanoma, suggesting a potential immunomodulatory role .

These expression patterns highlight PARVB's diverse functions across different biological contexts and support its potential significance in both normal physiological processes and pathological conditions, particularly in cancer.

What is known about PARVB's role in cancer progression, particularly melanoma?

Research has established several important aspects of PARVB's role in cancer:

• Overexpression pattern: PARVB is overexpressed in malignant melanoma and various other tumors, with expression levels significantly influencing prognosis in multiple cancer types .

• Prognostic indicator: Elevated PARVB expression is associated with poor prognosis in melanoma patients, suggesting its potential as a biomarker .

• Functional effects: Experimental studies show that silencing PARVB curtails cellular proliferation, migration, and invasion in vitro and decelerates tumor expansion in vivo, indicating its direct role in promoting cancer progression .

• Immune microenvironment: Augmented PARVB levels are inversely proportional to immunocyte penetration in melanoma, suggesting it may contribute to immune evasion mechanisms .

• Regulation: PARVB expression is elevated under hypoxic conditions through HIF-1α/2α activation. The HIF-1α/2α complex activates PARVB transcription by anchoring to hypoxia-specific responsive elements within the PARVB promoter .

These findings collectively indicate PARVB functions as a tumor promoter in melanoma through multiple mechanisms, including effects on cell proliferation and potential modulation of the tumor immune microenvironment.

How can I effectively design PARVB knockdown or knockout experiments?

To design effective PARVB knockdown or knockout experiments:

• Targeting strategy: For knockdown experiments, shRNA plasmids targeting PARVB have been successfully employed in previous studies. For knockout approaches, CRISPR-Cas9 systems have been used to target specific sites in the PARVB gene .

• Vector selection: Consider using lentiviral vectors for stable expression of shRNA constructs, as employed in previous research (e.g., GV248 backbone) .

• Target validation: After transfection or transduction, validate knockdown/knockout efficiency using:

  • Western blot to confirm protein reduction (using validated PARVB antibodies)

  • qRT-PCR to verify mRNA reduction

  • Sequencing of targeted regions in knockout clones

• Clone selection: For knockout studies, implement limiting dilution to isolate monoclones, followed by DNA sequencing to confirm the accuracy of the targeted sequence modifications .

• Functional assays: Design experiments to assess phenotypic changes, including:

  • Proliferation assays (MTT, BrdU incorporation)

  • Migration/invasion assays (transwell, wound healing)

  • In vivo tumor growth in appropriate animal models

• Controls: Include appropriate controls, such as non-targeting shRNA or scrambled CRISPR guide RNAs, to distinguish specific effects from non-specific responses to the expression system.

What approaches can be used to study the relationship between PARVB and hypoxia-inducible factors?

To investigate the relationship between PARVB and hypoxia-inducible factors (HIFs):

• Expression analysis under hypoxic conditions:

  • Culture cells under normoxic and hypoxic conditions (typically 1-2% O2)

  • Measure PARVB expression changes using qRT-PCR and Western blot

  • Use cobalt chloride (CoCl2) or deferoxamine (DFO) as chemical mimetics of hypoxia when physical hypoxia chambers are unavailable

• HIF overexpression studies:

  • Transfect cells with expression vectors containing HIF-1α and HIF-2α coding sequences (as done in published research)

  • Compare PARVB expression levels between HIF-overexpressing cells and control cells

  • Perform Western blot analysis to confirm both HIF expression and downstream PARVB upregulation

• Promoter analysis:

  • Identify potential hypoxia response elements (HREs) in the PARVB promoter region

  • Perform chromatin immunoprecipitation (ChIP) assays to verify HIF binding to these sites

  • Conduct luciferase reporter assays with wild-type and mutated HRE sites to quantify transcriptional activation

• Inhibitor studies:

  • Use HIF inhibitors to block hypoxia-induced PARVB upregulation

  • Employ RNA interference targeting HIF-1α and HIF-2α to distinguish their individual contributions

• Correlative analysis in tissue samples:

  • Perform co-immunostaining for PARVB and HIF-1α/2α in tumor samples

  • Analyze correlation between hypoxic regions (using markers like carbonic anhydrase IX) and PARVB expression

This systematic approach can help elucidate the precise mechanisms through which hypoxia and HIFs regulate PARVB expression and activity.

How can I integrate PARVB expression data with immune infiltration analysis in cancer research?

To integrate PARVB expression with immune infiltration analysis:

• Bioinformatic approaches:

  • Use established algorithms like TIMER2.0 to determine proportions of different immune cell types in tumor samples

  • Apply Spearman's correlation analysis to assess relationships between PARVB expression and infiltration of each immune cell type

  • Visualize data using R packages such as "ggpubr", "corrplot", and "ggplot2"

• Immune checkpoint correlation:

  • Obtain expression data for immune checkpoint (ICP) genes from databases like TCGA

  • Analyze associations between PARVB expression and each ICP gene using correlation analyses

  • Interpret results in the context of immune evasion mechanisms

• Experimental validation:

  • Perform multiplex immunofluorescence staining on tissue sections to simultaneously visualize PARVB and immune cell markers

  • Use flow cytometry to characterize immune populations in models with varied PARVB expression

  • Implement single-cell RNA sequencing to obtain high-resolution data on immune cell states and PARVB expression

• Functional studies:

  • Conduct co-culture experiments with immune cells and cancer cells with modified PARVB expression

  • Assess changes in immune cell recruitment, activation, and function

  • Evaluate cytokine/chemokine profiles in response to PARVB modulation

• In vivo immune monitoring:

  • Develop mouse models with PARVB knockout/overexpression

  • Monitor tumor immune infiltration over time

  • Test combination approaches with immunotherapies to assess potential synergistic effects

These integrated approaches can help establish mechanistic links between PARVB expression and immune regulation in the tumor microenvironment.

What are common issues when using PARVB antibodies and how can they be resolved?

Common issues and their solutions include:

• High background in immunostaining:

  • Issue: Especially problematic when using mouse-derived antibodies on mouse tissue.

  • Solution: Implement Mouse-On-Mouse blocking reagents as explicitly recommended for certain PARVB antibodies . Increase blocking time (5% BSA or normal serum), optimize antibody dilution, and extend washing steps.

• Multiple bands in Western blot:

  • Issue: Besides the expected bands at 42 kDa and 45 kDa, non-specific bands appear.

  • Solution: Optimize antibody dilution (try higher dilutions like 1:20000-1:50000) , increase blocking time, use more stringent washing conditions, and validate with positive controls. Consider using PARVB knockout samples as negative controls when available.

• Weak or no signal:

  • Issue: Antibody fails to detect PARVB despite expression in sample.

  • Solution: Verify sample preparation and protein integrity, optimize antigen retrieval for IHC (try both TE buffer pH 9.0 and alternative citrate buffer pH 6.0) , reduce antibody dilution, extend incubation time, and ensure compatible detection system.

• Inconsistent staining across experiments:

  • Issue: Variability in staining intensity between experimental replicates.

  • Solution: Standardize all protocol steps, prepare consistent antibody dilutions, maintain uniform incubation times and temperatures, and process all comparable samples simultaneously.

• False negative results in mouse samples:

  • Issue: Mouse-derived antibodies failing to work in mouse tissues.

  • Solution: As specified in product literature, "Mouse-On-Mouse blocking reagent may be needed for IHC and ICC experiments to reduce high background signal" . Consider alternative PARVB antibodies raised in different host species when working with mouse tissues.

How should I validate the specificity of PARVB antibodies in my experimental system?

Comprehensive validation of PARVB antibodies should include:

• Positive controls:

  • Use samples with confirmed PARVB expression, such as HeLa cells, mouse spleen tissue, mouse heart tissue, or rat heart tissue .

  • Include recombinant PARVB protein when available as a standard for Western blotting.

• Negative controls:

  • Employ PARVB knockout or knockdown samples as definitive negative controls.

  • For immunostaining, include secondary-only controls to assess non-specific binding.

• Peptide competition assays:

  • Pre-incubate the antibody with excess PARVB immunogen peptide before application.

  • Specific binding should be significantly reduced or eliminated.

• Multiple antibody validation:

  • Test multiple antibodies targeting different epitopes of PARVB.

  • Consistent results with different antibodies increase confidence in specificity.

• Cross-reactivity assessment:

  • Test the antibody on samples from different species to verify the claimed species reactivity.

  • Confirm absence of signal in species not listed in the reactivity profile.

• Molecular weight verification:

  • In Western blots, confirm detection at the expected molecular weights (42 kDa and 45 kDa for PARVB) .

  • Use molecular weight markers and positive controls for accurate comparison.

• Subcellular localization confirmation:

  • In immunofluorescence studies, verify that the staining pattern matches the expected subcellular distribution of PARVB.

  • Consider co-localization studies with markers of relevant cellular structures.

What are best practices for storage and handling of PARVB antibodies to maintain optimal activity?

To maintain optimal antibody activity:

• Storage conditions:

  • Store antibodies at -20°C for long-term preservation as recommended by manufacturers .

  • Most PARVB antibodies remain stable for one year after shipment when properly stored.

  • For antibodies containing 50% glycerol, aliquoting is generally unnecessary for -20°C storage .

• Aliquoting considerations:

  • For antibodies without glycerol or with lower glycerol content, prepare small aliquots to avoid repeated freeze-thaw cycles.

  • Use sterile tubes and aseptic technique when preparing aliquots.

• Handling precautions:

  • Allow antibodies to equilibrate to room temperature before opening to prevent condensation.

  • Centrifuge vials briefly before opening to collect liquid at the bottom.

  • Use clean, sterile pipette tips for each withdrawal to prevent contamination.

• Working solution preparation:

  • Prepare fresh working dilutions on the day of use whenever possible.

  • Use appropriate diluents, typically blocking buffer compatible with your application.

  • Store diluted antibody at 4°C if it must be kept for short periods (1-2 days).

• Buffer considerations:

  • Most PARVB antibodies are formulated in PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 .

  • Be aware that some formulations may contain 0.1% BSA, which may need to be considered in certain experimental designs .

• Contamination prevention:

  • Avoid microbial contamination by using sterile technique.

  • Monitor solutions for cloudiness or precipitation, which may indicate contamination or degradation.

• Shipping and temporary storage:

  • If receiving products shipped with polar packs, store immediately at the recommended temperature upon receipt .

  • For fluorophore-conjugated antibodies like PARVB Antibody with Janelia Fluor® 549, store at 4°C in the dark to prevent photobleaching .

How might PARVB antibodies be utilized in emerging cancer immunotherapy research?

PARVB antibodies could be instrumental in advancing cancer immunotherapy research through several approaches:

• Biomarker development:

  • Given that PARVB expression is inversely proportional to immune cell infiltration in melanoma , PARVB antibodies could help stratify patients for immunotherapy trials.

  • Develop immunohistochemical scoring systems using PARVB expression to predict response to immune checkpoint inhibitors.

• Mechanism investigation:

  • Use PARVB antibodies to investigate how PARVB overexpression contributes to immune evasion mechanisms.

  • Perform co-localization studies with immune checkpoint proteins to identify potential functional interactions.

• Therapeutic target validation:

  • Employ PARVB antibodies in preclinical studies to validate it as a potential target for combination with existing immunotherapies.

  • Investigate whether blocking PARVB function could enhance T-cell infiltration into tumors.

• Monitoring treatment response:

  • Develop protocols using PARVB antibodies to monitor changes in expression during immunotherapy treatment.

  • Correlate expression changes with clinical outcomes to identify patterns associated with response or resistance.

• Multiplex imaging approaches:

  • Integrate PARVB antibodies into multiplex immunofluorescence panels to simultaneously visualize PARVB expression and immune cell populations within the tumor microenvironment.

  • Apply spatial analysis to understand the relationship between PARVB-expressing cells and immune cell positioning.

These applications could help establish PARVB as both a predictive biomarker and a potential therapeutic target in cancer immunotherapy research.

What role might machine learning play in analyzing PARVB antibody-generated data?

Machine learning approaches could significantly enhance analysis of PARVB antibody-generated data:

• Image analysis automation:

  • Develop deep learning algorithms to quantify PARVB expression in immunohistochemistry and immunofluorescence images.

  • Train neural networks to recognize subtle patterns in PARVB distribution that correlate with disease progression.

• Multiparametric data integration:

  • Apply machine learning to integrate PARVB expression data with other molecular markers, clinical parameters, and treatment outcomes.

  • Identify complex patterns that may predict patient prognosis or treatment response better than PARVB expression alone.

• Spatial analytics:

  • Implement convolutional neural networks to analyze spatial relationships between PARVB-expressing cells and other cell types within the tumor microenvironment.

  • Identify neighborhood patterns that may indicate functional interactions.

• Antibody performance optimization:

  • Use machine learning to predict optimal antibody dilutions and protocol parameters based on sample characteristics.

  • Develop algorithms to distinguish specific from non-specific staining patterns.

• Literature mining:

  • Apply natural language processing to extract and synthesize knowledge about PARVB function from the scientific literature.

  • Generate hypotheses about PARVB's role in different biological contexts that can be tested experimentally.

While machine learning holds significant promise, researchers should be aware of challenges including the need for large, well-annotated datasets for training and validation, as well as potential biases in training data that could affect algorithm performance .